Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Time to reach steady state and prediction of steady-state concentrations for drugs obeying Michaelis-Menten elimination kinetics.

× No keyword cloud information.

11 in total

1. The kinetics of alcohol elimination in man.

Authors: F LUNDQUIST; H WOLTHERS
Journal: Acta Pharmacol Toxicol (Copenh) Date: 1958

2. A study of the pharmacokinetics of phenytoin (diphenylhydantoin) in epileptic patients, and the development of a nomogram for making dose increments.

Authors: A Richens
Journal: Epilepsia Date: 1975-11 Impact factor: 5.864

3. Bioavailability assessment: methods to estimate total area (AUC O to infinity) and total amount excreted (A infinity e) and importance of blood and urine sampling scheme with application to digoxin.

Authors: J G Wagner; J W Ayres
Journal: J Pharmacokinet Biopharm Date: 1977-10

Review 4. A modern view of pharmacokinetics.

Authors: J G Wagner
Journal: J Pharmacokinet Biopharm Date: 1973-10

5. Statistical considerations in the estimation of enzyme kinetic parameters by the direct linear plot andother methods.

Authors: A Cornish-Bowden; R Eisenthal
Journal: Biochem J Date: 1974-06 Impact factor: 3.857

6. Relationship between dose and plateau levels of drugs eliminated by parallel first-order and capacity-limited kinetics.

Authors: T Tsuchiya; G Levy
Journal: J Pharm Sci Date: 1972-04 Impact factor: 3.534

7. Explanation of dose-dependent decline of diphenylhydantoin plasma levels by fitting to the integrated form of the Michaelis-Menten equation.

Authors: N Gerber; J G Wagner
Journal: Res Commun Chem Pathol Pharmacol Date: 1972-05

8. Optimal phenytoin therapy: a new technique for individualizing dosage.

Authors: P W Mullen
Journal: Clin Pharmacol Ther Date: 1978-02 Impact factor: 6.875

Review 9. Plasma level monitoring of anticonvulsants.

Authors: M J Eadie
Journal: Clin Pharmacokinet Date: 1976 Impact factor: 6.447

10. Individualization of phenytoin dosage regimens.

Authors: T M Ludden; J P Allen; W A Valutsky; A V Vicuna; J M Nappi; S F Hoffman; J E Wallace; D Lalka; J L McNay
Journal: Clin Pharmacol Ther Date: 1977-03 Impact factor: 6.875

16 in total

Review 1. Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors: M Levine; T Chang
Journal: Clin Pharmacokinet Date: 1990-11 Impact factor: 6.447

Review 2. Nonlinear pharmacokinetics: clinical Implications.

Authors: T M Ludden
Journal: Clin Pharmacokinet Date: 1991-06 Impact factor: 6.447

Review 3. Rate and extent of drug accumulation after multiple dosing revisited.

Authors: Dion R Brocks; Reza Mehvar
Journal: Clin Pharmacokinet Date: 2010-07 Impact factor: 6.447

4. Classical Michaelis-Menten and system theory approach to modeling metabolite formation kinetics.

Authors: Jovan Popović
Journal: Eur J Drug Metab Pharmacokinet Date: 2004 Jul-Sep Impact factor: 2.441

5. Integrated equation to evaluate accumulation profiles of drugs eliminated by Michaelis-Menten kinetics.

Authors: G Lam; W L Chiou
Journal: J Pharmacokinet Biopharm Date: 1979-04

6. The computation of biomarkers in pharmacokinetics with the aid of singular perturbation methods.

Authors: Jie Ma; James P Keener
Journal: J Math Biol Date: 2018-07-28 Impact factor: 2.259

7. On the identification of Michaelis-Menten elimination parameters from a single dose-response curve.

Authors: K R Godfrey; W R Fitch
Journal: J Pharmacokinet Biopharm Date: 1984-04

Review 8. An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors: R D Pryka; K A Rodvold; S M Erdman
Journal: Clin Pharmacokinet Date: 1991-03 Impact factor: 6.447

9. Rapid and slow release phenytoin in epileptic patients at steady state: comparative plasma levels and toxicity.

Authors: R J Sawchuk; S M Pepin; I E Leppik; R J Gumnit
Journal: J Pharmacokinet Biopharm Date: 1982-08

10. Nomographic estimation of time to reach steady-state serum concentration during phenytoin therapy.

Authors: S Vozeh; F Follath
Journal: Eur J Clin Pharmacol Date: 1980-01 Impact factor: 2.953